"Today's decision reaffirms that there is simply no reliable scientific evidence that VIOXX caused the plaintiff's heart attack,"
Merck, known as MSD outside the United States and Canada, said today
that the Texas Supreme Court overturned a judgment in favor of the
family of Leonel Garza Sr. in a suit alleging that VIOXX caused Mr.
The San Antonio Court of Appeals had previously overturned the verdict
due to jury misconduct and ordered a new trial. The Texas Supreme Court
found that the evidence did not support the plaintiffs therefore ordered
final judgment in favor of Merck.
In today’s opinion, Justice Nathan L. Hecht wrote for the court: "we . .
. hold that the Garzas did not present reliable evidence of general
causation and are therefore not entitled to recover against Merck."
“Today's decision reaffirms that there is simply no reliable scientific
evidence that VIOXX caused the plaintiff's heart attack,” said Ted Mayer
of Hughes Hubbard & Reed, outside counsel for Merck.
The Texas Court of Appeals had reversed the jury's verdict and ordered a
retrial. The jury's original verdict on April 21, 2006 included $7
million in compensatory damages and $25 million in punitive damages. On
Dec. 21, 2006, the punitive award was reduced to $750,000 in compliance
with Texas statutory caps.
During the trial, Merck was represented by Richard L. Josephson and
Travis J. Sales of Baker Botts L.L.P., Houston, Texas. Merck's lead
appellate counsel is Baker Botts partner Stephen G. Tipps.
On Nov. 9, 2007, Merck announced that it had entered into an agreement
to resolve myocardial infarction and stroke claims filed as of that date
in the United States. The $4.85 billion program established by the
agreement resolved more than 99.9 percent of eligible claims in the
United States. The Garza case was excluded from the program.
Today's Merck is a global healthcare leader working to help the world be
well. Merck is known as MSD outside the United States and Canada.
Through our prescription medicines, vaccines, biologic therapies, and
consumer care and animal health products, we work with customers and
operate in more than 140 countries to deliver innovative health
solutions. We also demonstrate our commitment to increasing access to
healthcare through far-reaching policies, programs and partnerships. For
more information, visit www.merck.com.
This news release includes “forward-looking statements” within the
meaning of the safe harbor provisions of the United States Private
Securities Litigation Reform Act of 1995. Such statements may include,
but are not limited to, statements about the benefits of the merger
between Merck and Schering-Plough, including future financial and
operating results, the combined company’s plans, objectives,
expectations and intentions and other statements that are not historical
facts. Such statements are based upon the current beliefs and
expectations of Merck’s management and are subject to significant risks
and uncertainties. Actual results may differ from those set forth in the
The following factors, among others, could cause actual results to
differ from those set forth in the forward-looking statements: the
possibility that the expected synergies from the merger of Merck and
Schering-Plough will not be realized, or will not be realized within the
expected time period; the impact of pharmaceutical industry regulation
and health care legislation; the risk that the businesses will not be
integrated successfully; disruption from the merger making it more
difficult to maintain business and operational relationships; Merck’s
ability to accurately predict future market conditions; dependence on
the effectiveness of Merck’s patents and other protections for
innovative products; the risk of new and changing regulation and health
policies in the U.S. and internationally and the exposure to litigation
and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Additional factors that could cause results to differ
materially from those described in the forward-looking statements can be
found in Merck’s 2010 Annual Report on Form 10-K and the company’s other
filings with the Securities and Exchange Commission (SEC) available at
the SEC’s Internet site (www.sec.gov).